Table 1 Baseline characteristics of patients before and after IPTW adjustment
| Â | Number of patients | Percent distribution* | ||||
|---|---|---|---|---|---|---|
Characteristics | Olmesartan (n = 168) | Candesartan (n = 266) | Before adjustment | After adjustment | ||
| Â | Â | Â | Olmesartan | Candesartan | Olmesartan | Candesartan |
Age (years, mean ± SD) |  |  | 61.6 ± 12.4 | 60.9 ± 3.7 | 60.7 ± 13.9 | 61.0 ± 13.4 |
Sex (women, %) | 55 | 96 | 32.7 | 36.1 | 33.4 | 33.7 |
Medical history | Â | Â | Â | Â | Â | Â |
   Cerebrovascular disease | 30 | 49 | 17.9 | 18.4 | 18.5 | 17.7 |
   Ischemic heart disease | 39 | 34 | 23.2†| 12.8 | 17.5 | 16.7 |
   Other heart disease | 55 | 87 | 32.7 | 32.7 | 33.2 | 32.6 |
   Liver disease | 61 | 99 | 36.3 | 37.2 | 37.4 | 36.4 |
   Kidney disease | 76 | 104 | 45.2 | 39.1 | 43.9 | 42.1 |
   Thyroid disease | 29 | 61 | 17.3†| 22.9 | 21.7 | 20.6 |
   Diabetes mellitus | 141 | 171 | 83.9†| 64.3 | 72.6 | 71.8 |
   Hyperlipidemia | 144 | 215 | 85.7 | 80.8 | 82.2 | 82.6 |
   Gout | 2 | 12 | 1.2†| 4.5 | 1.6 | 3.2 |
   Malignant neoplasm | 49 | 99 | 29.2†| 37.2 | 36.0 | 34.7 |
Previous drugs | Â | Â | Â | Â | Â | Â |
   Chemotherapeutic drugs | 2 | 3 | 1.2 | 1.1 | 0.9 | 1.0 |
   Immunosuppressive drugs | 2 | 2 | 1.2 | 0.8 | 0.8 | 0.8 |
   Steroids | 8 | 14 | 4.8 | 5.3 | 5.1 | 5.1 |
   Thyroid drugs | 5 | 8 | 3.0 | 3.0 | 3.2 | 3.0 |
   Insulin | 26 | 21 | 15.5†| 7.9 | 10.4 | 10.1 |
   Oral hypoglycemic drugs | 54 | 64 | 32.1†| 24.1 | 27.4 | 27.5 |